Form 4: Director Luke Evnin Sells Werewolf Therapeutics Shares

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 274,619 shares of common stock via a Rule 10b5-1 trading plan.

Summary

• Director Luke Evnin sold a total of 274,619 shares of Werewolf Therapeutics (HOWL) common stock between April 30, 2026, and May 4, 2026.
• The sales were executed through various MPM BioImpact-affiliated entities.
• The transactions were conducted at weighted average prices ranging from $0.72 to $0.73 per share.
• Following these transactions, the reporting person maintains an indirect beneficial ownership of 1,679,330 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be perceived negatively, the use of a pre-planned 10b5-1 program suggests routine portfolio management rather than a reaction to negative internal developments.

Positives

• The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The sale of shares by a director and significant stakeholder may be perceived by some investors as a lack of confidence in the near-term stock performance.

Risks

• Continued selling pressure from major institutional shareholders could negatively impact the stock price.
• The company's stock is currently trading at a low valuation (sub-$1.00 range), which may present volatility risks.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is common in the biotechnology sector, particularly for venture capital firms managing fund lifecycles or rebalancing portfolios, and does not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to conduct orderly divestments while maintaining regulatory compliance.
• The sale prices are consistent with the current market trading range for small-cap clinical-stage biotechnology companies.

Related Party Transactions

• The shares sold were held by various MPM BioImpact-affiliated entities, including MPM Asset Management LLC and MPM BioVentures 2014, L.P., where the reporting person serves as a manager or director.

Stakeholder Impact

• Shareholders should note the reduction in indirect holdings by a key director, though the remaining stake remains significant.

Next Steps

• Monitor future Form 4 filings for additional divestment activity by the reporting person or other insiders.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Insider Trading, Form 4, Biotech, Luke Evnin, MPM BioImpact